October 4, 2021
Terumo Aortic today announced the successful implantation of the company's first custom made thoracoabdominal hybrid device to treat thoracoabdominal aortic disease.
The world's first thoracoabdominal repair procedure using a hybrid open-stent graft was carried out by Professor Sebastian Debus and supported by Professor Sabine Wipper at University Heart Centre Hamburg. This procedure represents a key stage in the development of a device for the treatment of patients with thoracoabdominal aortic disease using minimally invasive surgical techniques.
Utilising technology from the company's existing hybrid portfolio, the custom made thoracoabdominal hybrid device incorporates a harmonious combination of Terumo Aortic's Gelweave woven surgical and unique stent graft technology to address the patient's specific anatomy.
Professor Sebastian Debus, Chairman of the Department of Vascular Medicine, University Heart Centre Hamburg, Germany, commented: "This unique hybrid graft was designed in collaboration with Terumo Aortic to reduce the risk of complications associated with thoracotomy and extracorporeal circulation. The device consists of a proximal stent-graft for transabdominal retrograde delivery to the descending aorta combined with a distal six-branched abdominal device for open abdominal aortic repair. The preliminary end-to-side anastomosed branch to the iliac artery allows continuous retrograde flow to the distal aorta following proximal stent-graft deployment, and visceral vessels are subsequently anastomosed. This is the 'first-in-human' device implanted; it was easy to implant and the procedure was uneventful and straightforward. The patient showed 'fast track' recovery and postoperative course was without complications."
Mark Miles, Chief Commercial Officer at Terumo Aortic commented: "This milestone demonstrates our commitment to developing personalised solutions as part of our comprehensive surgical, endovascular and hybrid portfolio. Pushing forward with this type of innovation enables clinicians to treat a broader range of patients with anatomies that are not suitable for off-the-shelf products."
At Terumo Aortic, we partner with our customers to revolutionise aortic care. We deliver innovation, versatility and precision with the broadest range of solutions that can be personalised for every patient. We are further complementing our implantable device portfolio through thedevelopment of digital technologies.
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.
Corporate Communication Dept., Terumo Corporation
Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.
Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.